Microbion is developing innovative approaches for the prevention and treatment of infectious diseases by virtue of the broad-spectrum antimicrobial and anti-biofilm properties of the compounds derived from our novel platform technology. Microbion’s therapeutic pipeline includes compounds currently in Phase 2 clinical studies for diabetic foot ulcer infection and post-surgical orthopedic infections. We are also exploring the utility of our compounds for respiratory infection and systemic administration.
Based on efficacy observed in extensive research and pre-clinical studies, our compounds are anticipated to safely and effectively treat antibiotic-resistant infections including those caused by MRSA, VRE and many other resistant bacteria, including those implicated in respiratory infection. The potent anti-biofilm properties of Microbion’s compounds combined with their activity against antibiotic-resistant pathogens provides a novel and potentially game-changing strategy for treatment of infections.